Are you interested in HBV?
Let's look at our 'Year in Review' in @NatRevGastroHep to see the main discoveries in 2024 that redifine HBV-specific CD8+ T cell dysfunction.
Note: Disfunction is different from exhaustion!
Let's look at our 'Year in Review' in @NatRevGastroHep to see the main discoveries in 2024 that redifine HBV-specific CD8+ T cell dysfunction.
Note: Disfunction is different from exhaustion!
Excited to share our "Year in Review" perspective in @NatRevGastroHep, where @ValeFuma91 and I highlight key advances in understanding #HBV infection from 2024! We focused on three groundbreaking studies that redefine HBV-specific CD8+ T cell dysfunction:View quoted post on X
1️⃣ Heim et al. (@NatImmunol) unveiled a distinct subset of HBV-specific CD8+ T cells that, while attenuated, retain cytotoxic potential. They showed TGFβ signaling maintains this state, suggesting TGFβ inhibition could restore antiviral function.
🔗 nature.com/articles/s4159…
2️⃣ Bosch et al. (@Nature) demonstrated how liver sinusoidal endothelial cells (LSECs) suppress HBV-specific CD8+ T cell activation via cAMP–PKA signaling. This delicate balance limits viral clearance but prevents excessive liver damage.
🔗 nature.com/articles/s4158…
3️⃣ Andreata et al. (@CellCellPress), from our group, showed that co-signaling modulation via 4-1BB agonism reinvigorates dysfunctional HBV-specific CD8+ T cells, providing a promising alternative to checkpoint blockade.
🔗 cell.com/cell/fulltext/…
These studies underscore the complexity of CD8+ T cell dysfunction in chronic HBV and spotlight new therapeutic opportunities, from 4-1BB agonists to TGFβ inhibitors. 🧪🧬
Special thanks to @ERC, @AIRC_it, @EMBO_YIP, @ArmeniseHarvard, @SanRaffaeleMI, @MyUniSR, @ICE_HBV, @HepBFoundation, @EASLnews, and @AASLDtweets for supporting this field of research! nature.com/articles/s4157…